The results quantitatively revealed that both the CD31 and VEGF expression of the ADSC-E7’-eGFP–PE(ΔIII)-E7-KDEL3 combined treatment groups were significantly lower than the other single treatment or control groups (Figure 5C,D and Figure 5G,H), suggesting that the tumor regression induced by the combined treatment might be due to the inhibition of angiogenesis. The gene discussed is PECAM1; the disease is neoplasm.